{
    "ticker": "IBRX",
    "name": "Immunic, Inc.",
    "description": "Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of autoimmune and inflammatory diseases. Founded in 2016 and headquartered in New York, Immunic is dedicated to addressing significant unmet medical needs through its pipeline of oral therapeutics. The company's lead product candidate, IMU-838, is a selective oral drug designed to treat multiple sclerosis and other autoimmune diseases. Immunic is also advancing additional candidates, including IMU-935, aimed at treating psoriasis and other immune-mediated disorders. With a robust clinical development strategy, Immunic aims to bring novel treatment options to patients and transform the standard of care in the field of immunology. The company leverages advanced scientific research and development capabilities to drive the discovery and optimization of its drug candidates, collaborating with leading academic institutions and research organizations to enhance its therapeutic offerings. Immunic\u2019s mission is to provide breakthrough therapies that improve the quality of life for patients suffering from chronic and debilitating diseases, while maintaining a commitment to scientific excellence and integrity in all its endeavors.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2016",
    "website": "https://www.immunic-therapeutics.com",
    "ceo": "Daniel Vitt",
    "social_media": {
        "twitter": "https://twitter.com/immunicthera",
        "linkedin": "https://www.linkedin.com/company/immunictherapeutics/"
    },
    "investor_relations": "https://ir.immunic-therapeutics.com",
    "key_executives": [
        {
            "name": "Daniel Vitt",
            "position": "CEO"
        },
        {
            "name": "Marcel A. van Haperen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "IMU-838",
                "IMU-935"
            ]
        }
    ],
    "seo": {
        "meta_title": "Immunic, Inc. | Innovative Therapies for Autoimmune Diseases",
        "meta_description": "Learn about Immunic, Inc., a clinical-stage biopharmaceutical company developing innovative oral therapies for autoimmune diseases. Discover our pipeline and mission.",
        "keywords": [
            "Immunic",
            "Biopharmaceuticals",
            "Autoimmune Diseases",
            "IMU-838",
            "IMU-935",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does Immunic focus on?",
            "answer": "Immunic focuses on developing innovative therapies for autoimmune and inflammatory diseases."
        },
        {
            "question": "Who is the CEO of Immunic?",
            "answer": "Daniel Vitt is the CEO of Immunic, Inc."
        },
        {
            "question": "Where is Immunic headquartered?",
            "answer": "Immunic is headquartered in New York, New York, USA."
        },
        {
            "question": "What are Immunic's main products?",
            "answer": "Immunic's main products include IMU-838 and IMU-935."
        },
        {
            "question": "When was Immunic founded?",
            "answer": "Immunic was founded in 2016."
        }
    ],
    "competitors": [
        "AMGN",
        "ABBV",
        "VRTX",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "JNJ",
        "PFE",
        "MRNA"
    ]
}